The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

NCT02679196 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B Cell

Interventions

DRUG: KA2237

Sponsor

Karus Therapeutics Limited